Xenopax for the treatment of steroid-refractory acute graft-versus-host disease: the RELAX study.

ABSTRACT:

Background

Steroid-refractory (SR) acute graft-versus-host disease (aGVHD) is the major cause of early mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Xenopax, a novel and the only available humanized interleukin-2 (IL-2) receptor antagonist, has been approved as a category 2 biological product by the National Medical Products Administration. This study aims to evaluate the efficacy, safety, and prognostic factors of xenopax treatment for SR-aGVHD in real-world settings.

Methods

This was a multicenter, retrospective analysis that included SR-aGVHD patients who received xenopax at 17 hospitals across China. The data were collected from the electronic medical records in transplant databases. The primary endpoint was the 28-day overall response r

SUBMITTER: Cao LQ 

PROVIDER: S-EPMC12477784 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature